Tobiloba Oni A mutation+evolution driven state of enhanced fitness/robustness relative to its normal counterpart (at the cellular or tissue level). This happening at such an incredibly accelerated and uncoordinated manner at the expense of the host.

Tobiloba Oni At its core, a disorder characterized by cell uncontrolled proliferation

Tobiloba Oni I usually define it as cell selfishness, in which individual cells evolve to become independent from the rest, but taking advantage of the shared resources.

Tobiloba Oni A reversion from multicellular, diploid, sexual reproduction to unicellular, diploid, asexual reproduction. Metastasis, dormancy, and other cancer behaviors are best explained by evoluationary theory applied to individual cells residing the environment of the body.

Tobiloba Oni #cancer is Biologic Chaos

Tobiloba Oni For an overarching theme I propose "Reneging on a contract that balances cellular and organismal fitness."

Tobiloba Oni 💯 Incidentally, I recently talked about this very issue in a podcast (~ 6min mark): youtu.be/iyGBHvFEYug

Tobiloba Oni I consider it a disease of progressive tissue dysregulation that leads to eventual systemic failure. But I draw heavily from Tufts University Drs. Soto and Sonnenschein “TOFT” theory which IMO is by far the best explanation I’ve seen yet: ncbi.nlm.nih.gov/pmc/articles/P…

Ani Deshpande Tobiloba Oni Agreed. I’ve always thought that cancer is when cellular fitness becomes dominant over organismal fitness.

I ask for your help to support this Turkey Earthquake Fund gofundme.com/f/xh8d5t-turke… that will directly help affected families in the region. Thanks everyone who reached out during these difficult times, truly appreciate and will never forget your support ❤️ Please share this 🙏

Glyco enthusiasts from MIT (including Chemistry Professors Laura Kiessling, Barbara Imperiali, and Matt Shoulders) and beyond recently gathered in Bartos Theatre to enjoy presentations of the latest advancements in glycobiology research. chemistry.mit.edu/chemistry-news…

The company ran a 240 patient (!) randomized phase 2 trial of Simtuzumab in #PancreaticCancer that showed no therapeutic benefit. academic.oup.com/oncolo/article… As an angiogenesis inhibitor (versus the stated inhibition of LOXL2 catalytic activity) this was essentially a rerun of Gem

“There are not, and will never be, KRAS inhibitors” 👀 PascaLab presents a memorable reviewer comment from her 1st unfunded NIH grant at #AACRPan24. The lesson is that you should not let deflating reviewer comments define the value of your science. Also, persistence!

@NCICancerBio #PCAMChat24 A3: From a clinical/translational standpoint, we finally have drugs that can target KRAS in #PancreaticCancer. This gene is abnormal in >90% of cases, and it has taken four decades since the original discovery tofinally have a slew of drugs in the pipeline that can

.@EmilyAshkin et al Monte Winslow's Lab underscore important roles of STAG2 in suppressing lung tumorigenesis & highlight a STAG2-PAXIP1/PAGR1 tumor-suppressive program that may transcend cancer type. hubs.la/Q02-Y7_D0 Haiqing Xu King L Hung Howard Chang Jesse Dixon Zhichao Xu 徐志超